Chikungunya is a disease carried by Aedes mosquitoes that affects >100 countries, mostly in the tropics and subtropics (1). In the European Union (EU), chikungunya is not endemic, even though some outbreaks were reported in France and Italy after introduction of chikungunya virus by travelers into receptive areas (areas in which Aedes albopictus mosquitoes were established and active) (2–6).

To limit secondary transmission, it is crucial to monitor the distribution and activity of the mosquito vectors of the virus, reduce the likelihood of introduction of the virus by travelers, detect infections among returning travelers early, and implement timely control measures for cases in receptive areas. Consequently, surveillance of chikungunya was implemented during 2008 by the EU, whose goal was supporting these objectives (7).

We reviewed the surveillance data of travel-associated chikungunya cases reported in the EU during 2012–2018 with 2 aims. The first aim was to document factors associated with increased infection rates among travelers so that travelers, travel clinics, and public health authorities have relevant information to mitigate risks for infection. The second aim was to review how surveillance data could support preparedness against secondary transmission and timely control of outbreaks in susceptible areas.

Methods

Travelers
We obtained traveler data for 2012–2017 from the International Air Transport Association, which records passengers on commercial flights. We did not have access to 2018 data and considered it equal to 2017 data. We analyzed the number of travelers flying from chikungunya-affected countries to EU countries per month. We considered the departure and arrival countries irrespectively of connecting flights and assumed that case-patients were flying from the country in which infection occurred.

Travel-Related Cases
We defined a travel-related case-patient as a person reported by an EU country, later called reporting countries, with a probable or confirmed chikungunya infection acquired outside their country of residence during 2012–2018. Cases were reported to the European Centre for Disease Prevention and Control (ECDC) (8). For time-related analysis we used, in
order of preference, the date of onset, the date of diagnostics, or the date of notification. When none of these dates were available and if the date used for statistics was earlier than any of the dates mentioned, we used the date used for statistics, which is an unspecified, mandatory date.

We defined a probable case-patient as a person who had fever, returned from an area with ongoing chikungunya transmission within 2 weeks before onset of symptoms, and had virus-specific IgM in 1 serum sample (9). We defined a confirmed case-patient as a person satisfying any of the following laboratory criteria: detection of virus nucleic acid or virus isolation from a clinical specimen, virus-specific IgM in 1 serum sample plus confirmation by neutralization, or seroconversion or 4-fold antibody titer increase of specific antibodies in paired serum samples (9).

Vector Distribution and Population
For each year, we obtained data on establishment of Ae. albopictus mosquitoes at the regional level (third level of the Nomenclature of Territorial Units for Statistics [10]) from the VectorNet database (11) and the French Ministry of Health website (12) and the population in reporting countries from Eurostat (13). We calculated the percentage of the population in regions in which the vector was established (population living in regions in which Ae. albopictus mosquitoes were established × 100/total population in the country). We grouped countries per geographic regions according to the United Nations Statistics Division definitions (14).

Inclusion Criteria
The applied inclusion criteria (Appendix Figure, https://wwwnc.cdc.gov/EID/article/26/6/19-0490-App1.pdf) aimed to account for possible errors in gathering or reporting travel history/exposure of case-patients and lack of specificity of IgM serologic testing (15,16). We included probable and confirmed travel-related cases. Cases related to the French overseas territories (e.g., Martinique, French Polynesia) were considered as travel-related cases and those overseas territories as countries of infection. We also included reporting countries that submitted data every year and provided country of infection for ≥50% of their cases (arbitrary cutoff value) over the study period. When multiple countries of infection were reported for 1 case, the country of infection was changed to unknown. Finally, we included cases with a known country of infection; countries of infections that were associated with ≥2 cases, of which ≥1 was a confirmed case, and that were either reported by 2 reporting countries or reported over multiple years; and countries of infection that had travelers data available.

Analysis
To obtain information that could support prevention of cases among travelers, we performed a descriptive analysis of travel patterns, case characteristics, reporting countries, and countries of infection. As a proxy of the risk for infection, we calculated infection rates among travelers (TIR = no. cases/100,000 travelers).

To define the risk for secondary transmission, we conducted a (nonsystematic) literature search on occurrences of secondary transmission in the EU during 2012–2018 and estimated the number of cases that could have led to autochthonous outbreaks. We considered that travel-related cases were distributed evenly within the reporting countries; for each year and reporting country, we multiplied the number of travel-related cases that occurred during June–October (when the vector is more abundant and active) by the percentage of population in regions where Ae. albopictus mosquitoes were established. We did not consider secondary transmission by donations of substances of human origin. We performed statistical analyses by using STATA/SE 14.0 software (https://www.stata.com) and Microsoft Excel 2016 (https://www.microsoft.com).

Results
We identified 13 reporting countries and 59 countries of infection (Figure 1). During 2012–2018, a total of 146 million travelers arrived in reporting countries from countries of infection (Appendix Table). Most of these travelers arrived from Southeast Asia (27%), southern Asia (19%), and the Caribbean (15%). More specifically, 12% arrived from India, 12% from Thailand, and 8% from Brazil. The United Kingdom (31%), France (22%), and Germany (16%) received the highest number of travelers.

Travelers from the Caribbean (41%) and Polynesia (74%) arrived primarily in France. Travelers from South (32%) and Central (29%) America arrived mainly in Spain. Travelers from Southeast (32%) and southern (55%) Asia and from eastern Africa (44%) arrived primarily in the United Kingdom.

The overall yearly number of travelers increased during 2012–2018 from 18 million to 24 million. The highest increases in travelers during that period were for Northern Africa (88%), Central America (71%), and the Caribbean (54%). There were also large annual variations in number of travelers returning
Chikungunya Infections among EU Travelers

From specific countries of infection. For instance, the number of travelers from Venezuela decreased by 58% during 2013–2015 largely because of domestic insecurity and political crisis.

The number of EU travelers exhibited a seasonal pattern with peaks related to holiday periods (January, March, and August). Peak periods varied among reporting countries: March and August for France; January and March for Germany; July–September for Spain; January for Sweden; and January, April, and August for the United Kingdom.

**Risk for Infection among Travelers**

During 2012–2018, there were 2,616 travel-related chikungunya cases, among which 1,766 were confirmed cases and 850 were probable cases (Table 1). France (918), the United Kingdom (593), Spain (587), and Germany (359) reported 94% of the cases. Although most reporting countries reported mostly confirmed cases, 60% of the cases reported by France and 31% of the cases reported by the United Kingdom were confirmed. The global TIR was 1.8 cases/100,000 travelers (Appendix Table).

The number of cases and global TIR fluctuated over the study period (Table 1; Figure 2; Appendix Table); both values peaked in 2014. There was a seasonal increase in cases during May–September, with a peak in May–June for Spain, May–August for France, September–November for Germany, and October–November for the United Kingdom. The global TIR was highest in May, June, and July. The median age of travel-related case-patients was 43 years (interquartile range 32–55 years), and the female-to-male ratio was 1.1:4.

We observed 3 successive epidemiologic periods (Figures 2–5). The first phase, 2012–2013, had few cases, most (84%) associated with southern and Southeast Asia; the global TIR was 0.2. In November 2013, one case was associated with the Caribbean, marking the start of epidemics in the Americas (17).

The second phase, 2014–2015, corresponded to the globalization of virus circulation; the global TIR was 4.8. Most cases were associated with the Caribbean (68%) and South America (17%). In 2014, the TIR for travelers from the Caribbean reached 45.9; in 2015 it decreased in travelers from the Caribbean (1.6), but
it increased for travelers from South America (6.3) and Central America (6.1). In 2014, there was a high TIR for travelers returning from Haiti (266.6) and Dominica (193.6), and during 2015, a high TIR was associated with Honduras (78.1) and Nicaragua (76.5).

During the 2014–2015 phase, a high TIR was associated with Polynesia (36.8), which matched the intense epidemic in the region; in French Polynesia for instance, a few months after introduction of the virus, 25% of the population had been affected (18). In Africa, high TIRs were observed in travelers returning from Angola (12.0) during 2014 and Equatorial Guinea (9.2) during 2015. During that phase, travelers arriving in France and Spain had the highest TIRs: 9.5 for France and 9.8 for Spain.

The third phase, 2016–2018, was marked by a decrease in the global TIR. During that phase, a large percentage of case-patients were returning from southern Asia (45%) and South America (24%); regional TIRs were 2.1 for southern Asia and 1.4 for South America. During 2016, there were high TIRs for travelers returning from Bolivia (21.4) and Nicaragua (18.2). In Africa, high TIRs were seen for travelers from Somalia during 2016 (68.3) and Kenya during 2018 (6.6); a large epidemic affected Mombasa County in Kenya during 2018 (19). During 2016–2018, travelers arriving in Germany, Spain, Sweden, and the United Kingdom had TIRs ranging from 1.0 to 2.1, and travelers arriving in France had a TIR of 0.5.

### Risk for Secondary Transmission within the EU

During 2012–2018, a total of 3 autochthonous chikungunya outbreaks occurred in the EU. Two occurred in France in Hérault Department (September–October 2014) and Var Department (August 2017) (3,4). For the outbreak in Hérault, the index case-patient returned from Cameroon. For the outbreak in Var, the virus originated in Central Africa. One large outbreak occurred in the Lazio and Calabria regions of Italy (June–November 2017) (5). The index case-patient was not identified, but the virus originated in Pakistan or India (6,20).

During the study period, 10 case-patients returned from Cameroon (1–2/year). France reported the only case-patient during 2014; the TIR for travelers from France that year was 0.9. The highest TIR related to Cameroon was during 2017 for travelers returning from Cameroon (TIR = 28.5). During 2012–2018, a total of 38 case-patients were reported from Central Africa, 6 of them during 2017: 2 by France (TIR = 1.0) and 4 by Spain (TIR = 15.3). The highest TIRs related to Central Africa were in 2014 and 2017 among travelers from Spain (TIR = 17.3 during 2014 and 15.3 during 2017). During the study period, we detected 328 case-patients infected in India or Pakistan, 72 of them during 2017. Italy did not report any cases from these countries during 2017. During 2017, the TIR for travelers returning either from India or Pakistan was highest in the United Kingdom. The highest TIRs related to India or Pakistan were during 2016 among travelers from Malta and Slovenia. During 2014, travelers from France who had the highest TIRs (>600) were returning from Dominica, Suriname, and Tonga. During 2017, among travelers from France and Italy, those who had the highest TIRs returned from Bangladesh (TIR = 12.5 for travelers from France and 8.7 for travelers from Italy).

Among the reporting countries, France, Germany, Greece, Italy, Malta, Slovenia, and Spain had receptive areas (Table 2). The percentage of the population in regions in those countries colonized by *Ae. albopictus* mosquitoes increased during 2012–2018, from 28% in 2012 to 45% in 2018. We estimated that 270 travel-related case-patients returned to receptive areas during 2012–2018; 171 (63%) were in 2014. Among

---

**Table 1. Characteristics of 2,616 persons with travel-related chikungunya infections, 2012–2018**

| Characteristic       | No. case-patients (%) |
|----------------------|------------------------|
| Case classification  |                        |
| Probable             | 850 (32)               |
| Confirmed            | 1,766 (68)             |
| Sex                  |                        |
| F                    | 1,517 (58)             |
| M                    | 1,088 (42)             |
| Unknown              | 11 (<1)                |
| Age group, y         |                        |
| <1–4                 | 25 (1)                 |
| 5–14                 | 79 (4)                 |
| 15–24                | 154 (7)                |
| 25–44                | 936 (43)               |
| 45–64                | 775 (35)               |
| >65                  | 221 (10)               |
| Unknown              | 426 (16)               |
| Year of infection    |                        |
| 2012                 | 37 (1)                 |
| 2013                 | 45 (2)                 |
| 2014                 | 1,431 (55)             |
| 2015                 | 448 (17)               |
| 2016                 | 365 (14)               |
| 2017                 | 171 (7)                |
| 2018                 | 119 (6)                |
| Month of infection   |                        |
| January              | 133 (5)                |
| February             | 89 (3)                 |
| March                | 96 (3)                 |
| April                | 150 (5)                |
| May                  | 296 (11)               |
| June                 | 392 (15)               |
| July                 | 340 (13)               |
| August               | 284 (11)               |
| September            | 240 (9)                |
| October              | 220 (8)                |
| November             | 209 (8)                |
| December             | 167 (6)                |
Chikungunya Infections among EU Travelers

the estimated case-patients, 163 arrived in France, 79 in Spain, and 25 in Italy.

Discussion
We documented factors associated with increased travel-associated chikungunya cases reported in the EU during 2012–2018. Travel patterns (i.e., volume of travelers, country visited, and period of travel) were specific to each of the reporting countries. These patterns also reflect the geopolitical context, historical and cultural links, and preferences of travelers.

The TIR fluctuated according to the region/country visited, the reporting country, and the period of travel. The difference in TIR and seasonality among reporting countries was likely caused by difference in places visited within the countries of infection, intensity of virus circulation at the time of the visit, and reason for travel (e.g., business versus holidays). Generally, we observed a much higher TIR for travelers visiting a country with historical links to the reporting country (i.e., travelers from Spain visiting countries in Central America or travelers from France visiting French Overseas Countries and Territories). This finding might be explained by a high number of travelers visiting friends or relatives (VFR travelers). These travelers are less likely to receive pretravel advice than other types of travelers (21), might stay longer in the visited country, and might use fewer protective measures. Therefore, EU countries should consider issuing their own specific travel advice on the basis of countries most visited and those that have a higher risk for infection for their citizens. Prevention campaigns could be strengthened before and during peaks of cases and TIR, and be tailored to at-risk populations (e.g., VFR travelers). To reach these populations, travel advice could be provided online when flight tickets are purchased or through social media.

A high number of cases or high TIR might also highlight a sensitive surveillance system. This suggestion explains a slightly higher TIR among travelers from Sweden compared with other travelers during the 2012–2013 and 2016–2018 phases. With an overall number of travelers that is relatively low and a sensitive surveillance system, Sweden was able to test most possible case-patients and therefore detect a high proportion of cases among travelers.

As highlighted in other reports (22,23), travel-related cases are good indicators of the epidemiologic situation of the country visited because outbreaks are reflected by an increase in travel-related cases. Our results accurately highlighted the spread of the virus throughout the Americas, Polynesia, and eastern...
Africa. Therefore, travelers can be considered as sentinels, particularly in countries in which disease surveillance is limited (e.g., Somalia).

If there are few travelers, the likelihood of observing cases is limited. Therefore, having no cases associated with a specific country does not necessarily mean that no virus is circulating. It is useful to consider traveler data, and TIR provides a more accurate estimation of the risk for infection for travelers.

The higher proportion of female case-patients could be explained by the fact that women are at higher risk for development of severe symptoms and are therefore more likely to seek medical attention (24). In addition, more female travelers might be exposed. For instance, in Spain, 61% of the travel-related cases were VFR travelers (25); those travelers are expected to be persons who emigrated to Spain from disease-endemic countries, mostly from the Americas. A high proportion of persons born in Central America/Caribbean (64.5%) and South America (55.6%) and living in Spain are women (26). Therefore, we might consider that more female travelers were going to the Americas as VFR travelers and became infected during that visit.

The number of cases and TIR do not seem to correlate with the likelihood of occurrence of autochthonous outbreaks in reporting countries and the origin of the imported outbreak strain. We found no autochthonous outbreaks associated with epidemics in the Americas during 2014–2015. In contrast, we

---

**Figure 3.** Rates of chikungunya infections among European travelers by country, region of infection, and epidemiologic period, 2012–2018. Shown are the 30 countries with the highest rates of infection for each period. A) 2012–2013; B) 2014–2015; C) 2016–2018.
found 2 autochthonous outbreaks during 2017 despite the relatively lower number of imported cases than in previous years. The autochthonous outbreaks that occurred in the EU were not consistently associated with regions/countries of infections with most cases or high TIRs. In addition, although we estimated that pressure of introduction in receptive areas in Spain was higher than that for those in Italy, no outbreaks were reported in Spain. Also, outbreaks have not occurred in years that had higher pressure of introduction. Many other factors account for allowing an autochthonous outbreak, including activity and abundance of the vector, environmental factors, adaptation of the virus strain to the local vector, surveillance sensitivity, and timeliness of control measures implemented for imported cases (27–29). Consequently, although monitoring of outbreaks worldwide is relevant for estimating the risk for infection to travelers, this monitoring does not seem to be as relevant for estimation of the risk for secondary transmission.

In the absence of valid data on vector competence of local *Ae. Albopictus* mosquito populations and the particular chikungunya virus strain, each imported case should be considered as a potential index case. Control measures should then be implemented for the case to limit the likelihood of virus and disease spread.

In the context of the global climatic and ecologic changes, it is expected that *Ae. albopictus* mosquitoes will colonize new areas of the EU, thus creating new areas at risk for local transmission (30,31). Furthermore, the *Ae. aegypti* mosquito, another competent vector, is threatening to establish itself on the continent, increasing even more the risk for local transmission (32).

Surveillance systems in EU countries are diverse and have evolved over time (e.g., chikungunya became a mandatory reportable disease in Spain during 2014). Detailed information about national surveillance systems is available in the ECDC annual epidemiologic reports (33). Large outbreaks worldwide increased awareness among physicians, potentially enhancing testing of potential cases. Consequently,
comparisons between years and between reporting countries should be made cautiously.

Vector presence and activity in countries of infection vary at the local level, whereas we analyzed country level data. We did not have information about the reason for travel (e.g., tourism, business, VFR) and length of stay, 2 variables that are likely to influence the risk for infection (34,35). These biases were likely to be constant over time and did not affect interpretation of our results.

The reported travel-related cases only represent a fraction of the actual infections because ≥25% of infected persons remain asymptomatic (36). In parallel, 34% of cases were probable cases, diagnosed with 1 IgM test, a highly unspecific test that leads to a high number of false-positive results and, in some instances, indicates a previous infection (15,16,37,38). These biases were likely to be constant over time and place and therefore did not affect interpretation of our results.

We considered that all reported case-patients had viremia while in the EU and therefore could have contributed to secondary transmission. However, a study published in 2007 estimated that 63% of infected travelers were viremic upon return to their home country (39), which would suggest that we overestimated the number of potential index cases.

Several studies that assessed risk for travelers related to chikungunya and dengue used travelers data from the United Nation World Tourism Organization (22,40) or national databases 41,42). As highlighted in another report (43), there are major differences in the number of travelers between databases. The International Air Transport Association collects the number of flight passengers from 1 departure airport to an arrival airport, whereas other databases also include multicountry journeys and other types of travel mode, such as cruise ships; in addition, some databases might count travelers on the basis of their nationality instead of place of departure. We compared our results with those of 1 study that assessed the risk for chikungunya infection among travelers from Spain during 2008–2014 (22). Although results from the 2 studies are not in disagreement, they are not directly comparable. We believe that main difference in methods was that we used travelers data adjusted per year (except for 2018) and that the authors of the other study used mean annual number of travelers from previous years. If one considers major variations in number of travelers per year (e.g., Venezuela), we recommend researchers to used yearly number of travelers to estimate TIR. This recommendation emphasizes that comparison of TIRs between studies should be made with caution.

### Table 2. Estimated number of travel-related cases of chikungunya that could have led to secondary transmissions on the basis of cases reported during June–October and proportion of population in countries in which *Aedes albopictus* mosquitoes are established, per year and reporting country, 2012–2018

| Characteristic, year | France | Germany | Greece | Italy | Malta | Slovenia | Spain | Total |
|---------------------|--------|---------|--------|-------|-------|----------|--------|-------|
| No. travel-related case during June–October |        |         |        |       |       |          |        |       |
| 2012                | 7      | 3       | 0      | 2     | 0     | 0        | 0      | 12    |
| 2013                | 6      | 0       | 0      | 3     | 0     | 0        | 0      | 10    |
| 2014                | 540    | 65      | 1      | 0     | 0     | 0        | 180    | 806   |
| 2015                | 35     | 29      | 0      | 9     | 0     | 0        | 87     | 160   |
| 2016                | 16     | 28      | 1      | 9     | 0     | 1        | 31     | 86    |
| 2017                | 10     | 11      | 0      | 3     | 0     | 0        | 14     | 38    |
| 2018                | 5      | 7       | 1      | 2     | 0     | 0        | 2      | 17    |
| % Population in regions in which *Ae. albopictus* mosquitoes are established |        |         |        |       |       |          |        |       |
| 2012                | 21     | 0       | 6      | 83    | 92    | 11       | 20     | 28    |
| 2013                | 23     | 0       | 17     | 84    | 93    | 11       | 20     | 29    |
| 2014                | 25     | 0       | 25     | 86    | 93    | 14       | 20     | 31    |
| 2015                | 34     | 0       | 27     | 81    | 93    | 31       | 30     | 34    |
| 2016                | 36     | 0       | 76     | 99    | 93    | 57       | 33     | 41    |
| 2017                | 43     | 0       | 49     | 100   | 93    | 57       | 42     | 43    |
| 2018                | 55     | 1       | 83     | 100   | 93    | 57       | 42     | 45    |
| Estimated no. cases in regions in which *Ae. albopictus* are established |        |         |        |       |       |          |        |       |
| 2012                | 1      | 0       | 0      | 2     | 0     | 0        | 0      | 3     |
| 2013                | 1      | 0       | 0      | 3     | 0     | 0        | 0      | 4     |
| 2014                | 135*   | 0       | 0      | 0     | 0     | 0        | 36     | 171   |
| 2015                | 12     | 0       | 0      | 7     | 0     | 0        | 26     | 45    |
| 2016                | 6      | 0       | 1      | 9     | 0     | 1        | 10     | 26    |
| 2017                | 4*     | 0       | 0      | 3*    | 0     | 0        | 6      | 13    |
| 2018                | 3      | 0       | 1      | 2     | 0     | 0        | 1      | 6     |
| Total no. cases in regions in which *Ae. albopictus* are established |        |         |        |       |       |          |        |       |
| 2012–2018           | 163    | 0       | 2      | 25    | 0     | 1        | 79     | 270   |

*When an outbreak occurred.
In conclusion, monitoring the number of travel-related chikungunya cases and the TIR among travelers can support travel advice. However, our results showed no indication that these factors can be useful in estimating the risk for autochthonous outbreaks in EU countries.

Acknowledgments
We thank the members of the emerging and vector-borne disease network of the ECDC for their support of surveillance for chikungunya in the EU by providing chikungunya data and Henriette de Valk for reviewing and providing pertinent comments that helped improve the manuscript.

About the Author
Dr. Gossner is a veterinarian and principal expert in emerging and vector-borne diseases at the European Centre for Disease Prevention and Control, Solna, Sweden. Her primary research interests are emerging and vector-borne diseases.

References
1. Centers for Disease Control and Prevention. Where has chikungunya virus been found. 2018 May 29 [cited 2018 Dec 4]. https://www.cdc.gov/chikungunya/geo/index.html
2. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, et al.; CHIKV study group. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370:1840–6. https://doi.org/10.1016/S0140-6736(07)61779-6
3. Delisle E, Rousseau C, Broche B, Leparc-Goffart I, L’Ambert G, Cochet A, et al. Chikungunya outbreak in Montpellier, France, September to October 2014. Euro Surveill. 2015;20:21108. https://doi.org/10.2807/1560-7917.ES.2015.20.17.21108
4. Calba C, Guerbis-Galla M, Franke F, Jeannin C, Auzet-Caillaud M, Grard G, et al. Preliminary report of an autochthonous chikungunya outbreak in France, July to September 2017. Euro Surveill. 2017;22. https://doi.org/10.2807/1560-7917.ES.2017.22.39.17-00647
5. Vairo F, Mammo A, Lanini S, Nicostru E, Castilletti C, Carletti F, et al.; Chikungunya Lazio Outbreak Group. Local transmission of chikungunya in Rome and the Lazio region, Italy. PLoS One. 2018;13:e0208896. https://doi.org/10.1371/journal.pone.0208896
6. Venturi G, Di Luca M, Fortuna C, Remoli ME, Riccardo F, Severini F, et al. Detection of a chikungunya outbreak in Central Italy, August to September 2017. Euro Surveill. 2017; 22. https://doi.org/10.2807/1560-7917.ES.2017.22.39.17-00646
7. European Centre for Disease Prevention and Control. ECDC strategic multi-annual programme 2014–2020, 2014 [cited 2020 Mar 1]. https://ecdc.europa.eu/sites/portal/files/media/en/aboutus/Key%20Documents/Strategic-multiannual-programme-2014-2020.pdf
8. European Centre for Disease Prevention and Control. The European Surveillance System (TESSy) [cited 2018 Mar 7]. https://ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy
9. European Commission. Commission implementing decision 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Luxembourg: Office of the European Union; 6.7.2018:L170/1 [cited 2020 Mar 3]. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945&from=EN#page=13
10. European Commission. Eurostat. Nomenclature of territorial units for statistics [cited 2019 Feb 5]. http://ec.europa.eu/eurostat/web/nuts/overview
11. European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA). VectorNet: a European network for sharing data on the geographic distribution of arthropod vectors, transmitting human and animal disease agents. Mosquito maps [cited 2018 Dec 4]. https://ecdc.europa.eu/en/disease-vectors/surveillance-and-disease-data/mosquito-maps
12. Ministry of Solidarity and Health. Presence maps of the tiger mosquito (Aedes albopictus) in mainland France, Nov 28, 2018 [in French] [cited 2019 Feb 7]. https://solidarites-sante.gouv.fr/sante-et-environnement/risques-microbiologiques-physiques-et-chimiques/especes-nuisibles-et-parasites/article/cartes-depresence-du-moustique-tigre-aedes-albopictus-en-france-metropolitaine
13. Eurostat, the statistical office of the European Union. Population on 1 January by age group, sex and NUTS 3 region [cited 2019 Mar 9]. https://ec.europa.eu/eurostat/web/products-datasets/product?code=demo_r_piangrpr3
14. United Nations Statistics Division. Standard country or area codes for statistical use [cited 2017 Dec 15]. https://unstats.un.org/unsd/methodology/m49
15. Calba C, Franke F, Brottet E, Terrant G, Fournet N, Ovize A, et al. Specificity of chikungunya serology and epidemiological surveillance. Presented at: 39th Interdisciplinary Meeting of Anti-Infectious Chemotherapy; 2019 Dec 16–17; Paris, France [cited 2020 Mar 1]. https://sdbib.org/wp-content/uploads/2019/09/RICAI_Programme.pdf
16. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparc-Goffart I. Evaluation of commercially available serologic diagnostic tests for chikungunya virus. Emerg Infect Dis. 2014;20:2129–32. https://doi.org/10.3201/eid2014.1214269
17. Staples JE, Fischer M. Chikungunya virus in the Americas: what a vectorborne pathogen can do. N Engl J Med. 2014;371:887–9. https://doi.org/10.1056/NEJMmp1407698
18. World Health Organization, Regional Office of Western Pacific. Pacific syndromic surveillance report, Week 4 ending 25 Jan 2015 [cited 2019 Jan 30]. http://www.wpro.who.int/southpacific/programmes/communicable_diseases/disease_surveillance_response/PS6-25-January-2014/en
19. World Health Organization. Disease outbreak news: chikungunya—Mombasa, Kenya, Feb 27, 2018 [cited 2018 Dec 6]. https://www.who.int/csr/don/27-february-2018-chikungunya-kenya/en
20. Lindh E, Argentini C, Remoli ME, Fortuna C, Faggioni G, Benedetti E, et al. The Italian 2017 outbreak chikungunya virus belongs to an emerging Aedes albopictus—adapted virus cluster introduced from the Indian subcontinent. Open Forum Infect Dis. 2018;3:e006321.
21. Warne B, Weld LH, Cramer JP, Field VK, Grobusch MP, Caumes E, et al.; EuroTravNet Network. Travel-related infection in European travelers, EuroTravNet 2011. J Travel Med. 2014;21:248–54. https://doi.org/10.1111/jtm.12120
22. Fernandez-Garcia MD, Bangert M, de Ory F, Potente A, Hernandez L, Lasala F, et al. Chikungunya virus infections among travellers returning to Spain, 2008 to 2014. Euro
SYNOPSIS

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 6, June 2020

https://doi.org/10.3201/ eid2606a03

10.1128/JTM.00685-17

J Travel Med. 2018;25. https://doi.org/10.1093/jtm/tax072

25. National Center for Epidemiology, CIBER Epidemiology and Public Health (CIBERESP), Carlos III Health Institute. Results for epidemiological surveillance on communicable diseases. Annual report 2016, 2018 [in Spanish] [cited 2020 Mar 1]. www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/RENAVE_INFORME_ANUAL_2016

26. National Institute of Statistics. Foreign population per country of birth, age (five-year grouping) and gender, Jan 1, 2018 [in Spanish] [cited 2020 Mar 1]. https://www.ine.es/dynt3/inbase/es/index.htm?type=pcaxis&path=/t20/e245/p08/&file=pcaxis&dh=0&capsel=0

27. Manica M, Guzzetta G, Poletti P, Filipponi F, Solimini A, Caputo B, et al. Transmission dynamics of the ongoing chikungunya outbreak in central Italy: from coastal areas to the metropolitan city of Rome, summer 2017. Euro Surveill. 2017;22. https://doi.org/10.2807/1560-7917.ES.2017.22.44.17-00685

28. Tjaden NB, Suk JE, Fischer D, Thomas SM, Beierkuhnlein C, Semenza JC. Modelling the effects of global climate change on chikungunya transmission in the 21st century. Sci Rep. 2017;7:3813. https://doi.org/10.1038/s41598-017-03566-3

29. Solimini AG, Manica M, Rosà R, Della Torre A, Caputo B, et al. Transmission risk of dengue, chikungunya and Zika outbreaks in a large European city, summer 2017. Exp Ther Med. 2018;15:2634–42. https://doi.org/10.1086/590003

30. Gossner CM, Ducheyne E, Schaffner F. Increased risk for autochthonous vector-borne infections transmitted by Aedes albopictus in continental Europe. Euro Surveill. 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.24.1800268

31. Cunze S, Kochmann J, Koch LK, Klimpel S. Aedes albopictus and its environmental limits in Europe. PLoS One. 2016;11:e0162116. https://doi.org/10.1371/journal.pone.0162116

32. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. eLife. 2015;4:e08347. https://doi.org/10.7554/eLife.08347

33. European Centre for Disease Prevention and Control. Annual epidemiological reports (AERs) [cited 2019 Dev 17]. https://www.ecdc.europa.eu/en/annual-epidemiological-reports

34. Massad E, Rocklov J, Wilder-Smith A. Dengue infections in non-immune travellers to Thailand. Epidemiol Infect. 2013;141:412–7. https://doi.org/10.1017/S0950268812000507

35. Schwartz E, Wold L, Wilder-Smith A, von Sonnenburg F, Keystone JS, Kain KC, et al.; GeoSentinel Surveillance Network. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997–2006. Emerg Infect Dis. 2008;14:1081–8. https://doi.org/10.3201/eid1407.071412

36. Centers for Disease Control and Prevention. Infections diseases related to travel: chikungunya. In: CDC Yellow Book, 2018: Health Information for International Travel. New York: Oxford University Press; 2017.

37. Borgherini G, Poubpeau E, Joussaume A, Gouix A, Cotte L, Michaud A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008;47:469–75. https://doi.org/10.1086/590835

38. Grivard P, Le Roux K, Laurent P, Fianu J, Perrau J, Gigan J, et al. Molecular and serological diagnosis of chikungunya virus infection. Pathol Biol (Paris). 2007;55:490–4. https://doi.org/10.1016/j.patbio.2007.07.002

39. Lambert J, Couturier E, Vaillant V. Chikungunya infection, descriptive study of cases imported into mainland France, 2005–2006; 2007. Saint Maurice: InVS [in French] [cited 2020 Mar 1]. https://www.vie-publique.fr/sites/default/files/rapport/pdf/074000355.pdf

40. Rocklov J, Lohr W, Hjertqvist M, Wilder-Smith A. Attack rates of dengue fever in Swedish travellers. Scand J Infect Dis. 2014;46:412–7. https://doi.org/10.3109/00365548.2014.87222

41. Fukusumi M, Arashi T, Arima Y, Matsui T, Shimada T, Kinoshi T, et al. Dengue sentinel traveler surveillance: monthly and yearly notification trends among Japanese travelers, 2006–2014. PLoS Negl Trop Dis. 2016;10:e0004924. https://doi.org/10.1371/journal.pntd.0004924

42. Lau CL, Weinstein P, Slaney D. Dengue surveillance by proxy: travellers as sentinels for outbreaks in the Pacific Islands. Epidemiol Infect. 2013;141:2328–34. https://doi.org/10.1016/S0950-2688(15)000088-3

43. Behrens RH, Carroll B. The challenges of disease risk ascertainment using accessible data sources for numbers of travelers. J Travel Med. 2013;20:296–302. https://doi.org/10.1111/jtm.12062

Address for correspondence: Céline M. Gossner, European Centre for Disease Prevention and Control, Gustav III:s Blvd 40, 168 73 Solna, Sweden; email: celine.gossner@ecdc.europa.eu
### Appendix

**Appendix Table.** Travelers returning from countries of infection, chikungunya cases and rates of infection among travelers, per reporting country and per region of infection, 2012–2018

| Region of infection | Variable | Czech Republic | France | Germany | Greece | Hungary | Ireland | Italy | Latvia | Malta | Slovenia | Spain | Sweden | United Kingdom | Total |
|---------------------|----------|----------------|--------|---------|--------|---------|---------|-------|--------|-------|----------|-------|--------|----------------|-------|
| South America       | No. cases | 2              | 60     | 88      | 1      | 1       | 20      | 1     | 4      | 0     | 0        | 0     | 0      | 256            | 3     |
| No. travelers       | 162,021   | 4,903,438      | 3,047,638 | 173,748 | 111,014 | 276,454 | 4,295,986 | 12,123 | 28,604 | 9,766 | 7,893,846 | 399,818 | 3,180,034 | 24,494,490    | 471   |
| No. cases/100,000   | 1.2      | 1.2            | 2.9     | 0.6     | 0.0    | 0.0     | 0.5     | 8.2   | 0.0    | 0.0   | 3.2      | 3.3   | 0.9    | 1.9            |       |
| Caribbean           | No. cases | 3              | 723     | 113     | 1      | 0       | 0       | 1     | 0      | 0     | 0        | 0     | 208    | 10             | 229   |
| No. travelers       | 72,741    | 9,174,056      | 3,275,191 | 124,203 | 51,204  | 184,373 | 1,842,732 | 7,197  | 5,918  | 2,999 | 2,565,094 | 166,131 | 5,093,514 | 22,565,353    |       |
| No. cases/100,000   | 4.1      | 7.9            | 3.5     | 0.8     | 0.0    | 0.0     | 0.1     | 0.0   | 0.0    | 0.0   | 8.1      | 6.0   | 4.5    | 5.7            |       |
| Polynesia           | No. cases | 0              | 25      | 2       | 0      | 0       | 0       | 0     | 0      | 0    | 0        | 0     | 0      | 1              | 31    |
| No. travelers       | 2,173     | 229,507        | 20,939  | 311     | 640    | 648     | 29,670  | 48    | 4      | 1     | 24,277   | 1,305  | 19,942  | 309,492        |       |
| No. cases/100,000   | 0.0      | 10.9           | 9.6     | 0.0     | 156.3  | 0.0     | 3.4     | 0.0   | 0.0    | 0.0   | 76.6     | 5.0   | 10.0   |                |       |
| Southeast Asia      | No. cases | 6              | 36      | 44      | 0      | 2       | 5       | 0     | 0      | 0    | 13       | 22    | 41     | 170            |       |
| No. travelers       | 900,842   | 7,452,958      | 9,180,076 | 471,147 | 394,600 | 737,448 | 3,906,500 | 60,746 | 57,290 | 25,785 | 1,926,236 | 2,247,704 | 12,763,650 | 40,124,882    |       |
| No. cases/100,000   | 0.7      | 0.5            | 0.5     | 0.0     | 0.5    | 0.0     | 0.1     | 0.0   | 0.0    | 3.9   | 0.7      | 1.0   | 0.3    | 0.4            |       |
| Southern Asia       | No. cases | 1              | 8       | 14      | 1      | 1       | 0       | 4     | 0      | 0    | 0        | 4     | 4      | 65             | 100   |
| No. travelers       | 312,422   | 2,682,308      | 3,665,391 | 309,442 | 159,751 | 420,886 | 3,080,787 | 32,955 | 25,205 | 13,289 | 1,320,540 | 658,255 | 15,589,994 | 28,281,225    |       |

*Article DOI: https://doi.org/10.3201/eid2606.190490*
| Region of infection | Variable | Czech Republic | France | Germany | Greece | Hungary | Ireland | Italy | Latvia | Malta | Slovenia | Spain | Sweden | United Kingdom | Total  |
|---------------------|----------|----------------|--------|---------|--------|---------|---------|-------|--------|--------|----------|-------|--------|----------------|-------|
| % travelers         | No. cases/100,000 travelers | 0.6 | 1.1 | 1.3 | 1.3 | 0.6 | 1.3 | 0.0 | 0.5 | 0.0 | 4.0 | 7.5 | 1.1 | 2.0 | 1.5 | 1.3 |
| Eastern Africa      | No. cases | 2 | 6 | 13 | 0 | 3 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 34 | 69 |
| % cases             | No. travelers | 37.692 | 504.745 | 883.014 | 30.500 | 18.575 | 89.010 | 763.530 | 2.333 | 3.518 | 2.244 | 141.782 | 318.628 | 2,160.906 | 4,996.477 |
| % travelers         | No. cases/100,000 travelers | 5.3 | 1.2 | 1.5 | 0 | 16.2 | 4 | 0.4 | 0 | 0 | 0.0 | 0.7 | 0.9 | 0.7 | 1.9 | 1.6 | 1.4 |
| Central Africa      | No. cases | 0 | 16 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 2 | 38 |
| % cases             | No. travelers | 0.900 | 1,616.405 | 240.661 | 11.459 | 5.699 | 16.992 | 317.675 | 3.622 | 1.814 | 1.080 | 203.446 | 21.987 | 531.186 | 2,979.926 |
| % travelers         | No. cases/100,000 travelers | 0.0 | 1.0 | 2.5 | 0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.9 | 0.0 | 0.4 | 0.3 | 1.3 |
| Northern Africa     | No. cases | 0 | 18 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 2 | 3 |
| % cases             | No. travelers | 1,758 | 18.934 | 56.647 | 7.915 | 2.849 | 10.549 | 34.015 | 141 | 964 | 166 | 16.2 | 30.0 | 109 | 720 | 260.867 |
| % travelers         | No. cases/100,000 travelers | 1.0 | 7 | 20 | 3 | 1 | 4 | 12 | 0 | 0 | 0 | 0 | 2 | 11 | 39 | 100 |
| Western Africa      | No. cases | 0 | 6 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 6 | 1 | 9 | 24 |
| % cases             | No. travelers | 0.371 | 2,973.007 | 486.875 | 37.915 | 18.670 | 169.197 | 1,446.465 | 2.925 | 3.649 | 1.299 | 527.591 | 91.501 | 2,856.817 | 8,638.282 |
| % travelers         | No. cases/100,000 travelers | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.3 | 0.3 |
| Total               | No. cases | 16 | 918 | 359 | 4 | 8 | 1 | 51 | 2 | 1 | 2 | 587 | 74 | 593 | 2,616 |
| % cases             | No. travelers | 1,621 | 32,078.551 | 22,824.463 | 1,232.561 | 816.719 | 2,124.123 | 17.401.424 | 137.504 | 131.066 | 59.753 | 18,490.053 | 4,144.784 | 45,236.380 | 146,290.411 |
| % travelers         | No. cases/100,000 travelers | 1.0 | 2.9 | 1.6 | 0.3 | 1.0 | 0.0 | 0.3 | 1.6 | 0.8 | 0.0 | 3.3 | 3.2 | 1.8 | 1.3 | 1.8 |
| Inclusion criteria for study of risks related to chikungunya infections among European Union travelers, 2012–2018 |
|---------------------------------------------------------------|
| **All cases of chikungunya reported through The European Surveillance System between 2012 and 2018** |
| Number of reporting countries: 19 (AT, BE, CZ, DE, EL, ES, FI, FR, HU, IE, IT, LV, MT, NL, PT, RO, SE, SI and UK) |
| Number of cases reported: 3581 |
| Number of countries of infection: 92* |

| Probable and confirmed travel-related cases |
|--------------------------------------------|
| Number of reporting countries: 19 (AT, BE, CZ, DE, EL, ES, FI, FR, HU, IE, IT, LV, MT, NL, PT, RO, SE, SI and UK) |
| Number of cases reported: 3268 |
| Number of countries of infection: 91 |

| Reporting countries that submitted data every year and provided country of infection for at least 50% of their cases over the study period |
|----------------------------------------------------------------------------------------------------------------------------------|
| Number of reporting countries: 13 (CZ, DE, EL, ES, FR, HU, IE, IT, LV, MT, SE, SI and UK) |
| Number of cases reported: 3086 |
| Number of countries of infection: 89 |

| Cases with known country of infections |
|---------------------------------------|
| Number of reporting countries: 13 (CZ, DE, EL, ES, FR, HU, IE, IT, LV, MT, SE, SI and UK) |
| Number of cases reported: 2666 |
| Number of countries of infection: 89 |

| Countries of infections that were associated to at least two cases, of which one or more is a confirmed case, and that were either reported by two different reporting countries or reported over multiple years |
|----------------------------------------------------------------------------------------------------------------------------------|
| Number of reporting countries: 13 (CZ, DE, EL, ES, FR, HU, IE, IT, LV, MT, SE, SI and UK) |
| Number of cases reported: 2621 |
| Number of countries of infection: 60 |

| Countries of infection with travelers data available |
|-----------------------------------------------------|
| Number of reporting countries: 13 (CZ, DE, EL, ES, FR, HU, IE, IT, LV, MT, SE, SI and UK) |
| Number of cases reported: 2616 |
| Number of countries of infection: 59** |

*Afghanistan, Angola, Antigua and Barbuda, Argentina, Australia, Bangladesh, Benin, Bolivia, Brazil, British Virgin Islands, Burkina Faso, Cambodia, Cameroon, Central African Republic, Colombia, Congo, Cook Islands, Costa Rica, Cuba, Democratic Republic of the Congo, Djibouti, Dominica, Dominican Republic, East Timor, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, France, French Guiana, French Polynesia, Gabon, Ghana, Grenada and Saint Kitts and Nevis, Guatemala, Guinea, Haiti, Honduras, India, Indonesia, Ireland, Iraq, Ivory Coast, Jamaica, Kenya, Malaysia, Maldives, Mali, Marshall Islands, Martinique, Mauritius, Mexico, Montserrat, Mozambique, Myanmar, Nicaragua, Nigeria, Pakistan, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Portugal, Puerto Rico, Saint Lucia, Saint Vincent and the Grenadines, San Marino, Senegal, Sierra Leone, Singapore, Sint Maarten, Somalia, Sri Lanka, Sudan, Suriname, Togo, Tonga, Trinidad and Tobago, Uganda, United States, Vietnam, Western Samoa and Zimbabwe

**Angola, Bangladesh, Barbados, Bolivia, Brazil, Burkina Faso, Cambodia, Cameroon, Colombia, Congo, Costa Rica, Cuba, Democratic Republic of the Congo, Dominica, Dominican Republic, Ecuador, El Salvador, Equatorial Guinea, Eritrea, French Guiana, French Polynesia, Gabon, Grenada and Saint Kitts and Nevis, Guatemala, Guyana, Haiti, Honduras, India, Indonesia, Ivory Coast, Jamaica, Kenya, Malaysia, Martinique, Mexico, Nicaragua, Nigeria, Pakistan, Paraguay, Peru, Philippines, Saint Lucia, Saint Vincent and the Grenadines, Senegal, Singapore, Sint Maarten, Somalia, Sri Lanka, Sudan, Suriname, Togo, Tonga, Trinidad and Tobago, Uganda, United States, Vietnam, and Western Samoa

Appendix Figure. Inclusion criteria for study of risks related to chikungunya infections among European Union travelers, 2012–2018.